指南与共识前列腺癌

EAU-EANM共识声明:前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在前列腺癌患者中的作用及与[177Lu]Lu-PSMA放射配体治疗的关系

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy.
指南 / 共识 · Eur Urol Oncol · 2022-06-11

由21名前列腺癌专家组成的专家组通过电子德尔菲法和会议讨论,就PSMA PET/CT的应用及[177Lu]Lu-PSMA治疗提出36条声明,其中33条达成共识。共识强调PSMA PET/CT作为影像工具指导[177Lu]Lu-PSMA治疗应有适当使用指征。

要点

  • 21名专家通过德尔菲法对36条声明投票,33条达成共识。
  • 共识涵盖PSMA PET/CT效用、临床使用、示踪剂选择、患者选择及[177Lu]Lu-PSMA治疗管理。
  • 采用PSMA PET/CT指导[177Lu]Lu-PSMA治疗应有适当使用指征支持。

核心结论

  • 采用PSMA PET/CT作为影像工具指导[177Lu]Lu-PSMA治疗应有适当使用指征支持。

研究设计与样本

  • 来自不同学科的21名前列腺癌专家组成专家组,接受主题和相关文献,通过第一轮电子德尔菲法远程完成问卷,随后进行为期1天的会议讨论并包括第二轮德尔菲法。
  • 专家组成员对声明进行匿名投票,采用9分李克特量表(1=强烈不同意至9=强烈同意),计算中位数得分并使用兰德公司(RAND)提出的方法评估共识。

主要发现

  • 声明涵盖以下主题:PSMA PET/CT效用、临床使用和示踪剂选择;患者选择;接受[177Lu]Lu-PSMA治疗的转移性前列腺癌患者的管理。
  • 36条声明中33条达成共识。

关键数值与推荐

  • 36条声明中33条达成共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 组内偏倚是潜在局限性,因为一些声明在1天会议讨论期间被重新措辞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined. OBJECTIVE: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance. DESIGN, SETTING, AND PARTICIPANTS: A panel of 21 PCa experts from various disciplines received thematic topics and relevant literature. A questionnaire to assess proposed guidance statements regarding PSMA PET/CT and [177Lu]Lu-PSMA therapy was developed for completion remotely in a first e-Delphi round. A subsequent panel discussion was conducted during a 1-d meeting, which included a second Delphi round. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists voted anonymously on statements using a nine-point Likert scale from 1 = strongly disagree to 9 = strongly agree. Median scores were calculated and consensus was assessed using methods proposed by the Research and Development (RAND) corporation. RESULTS AND LIMITATIONS: Statements were developed to cover the following topics: PSMA PET/CT utility, clinical use, and choice of tracer; patient selection; and management of patients receiving [177Lu]Lu-PSMA for metastatic PCa. Consensus was reached for 33/36 statements. In-group bias is a potential limitation, as some statements were rephrased during discussions at the 1-d meeting. CONCLUSIONS: Adoption of PSMA PET/CT as an imaging tool to guide [177Lu]Lu-PSMA therapy should be supported by indications for appropriate use. PATIENT SUMMARY: A panel of experts in prostate cancer reached a consensus for the majority of statements proposed regarding the role of prostate-specific membrane antigen (PSMA)-based imaging and therapy, particularly the use of PSMA-based imaging in patients suitable for [177Lu]Lu-PSMA therapy and the need to perform PSMA-based imaging before considering patients as candidates for this therapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Fanti S, Briganti A, Emmett L, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022. PMID: 35697600. doi:10.1016/j.euo.2022.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。